ALPROLIX® offers acute bleed control your on-demand patients can trust, no matter their age1
Most bleeding episodes resolved with just 1 infusion1-3:
Kids B-LONG:
75% (n=45/60)
Aged 1-11 years
B-LONG:
90% (n=575/636)
Aged ≥12 years
PUPs B-LONG:
87%
(n=74/85)
Aged <18 years
Response to first infusion was rated as excellent or good,* with abrupt or definite pain relief and/or improvement in signs of bleeding1,2,4:
Kids B-LONG:
89% (n=47/53)
Aged 1-11 years
B-LONG:
84% (n=513/613)
Aged ≥12 years
PUPs B-LONG:
91% (n=72/79)
Aged <18 years
In B-LONG, the median overall ABR for adults and adolescents treated on-demand was1:
17.69 (10.77-23.24)
*Seven first injections for bleeding episodes in children were not evaluated for response and are excluded from this analysis.1
Excellent response was defined as abrupt pain relief and/or improvement in signs of bleeding. Good response was defined as definite pain relief and/or improvement in signs of bleeding but possibly requiring another injection in 1-2 days.1,4
Clinical trial information
Kids B-LONG was a phase 3 open-label study that investigated the safety and efficacy of
ALPROLIX in 30 previously treated pediatric patients with severe hemophilia B. Fifteen patients
were 1 to 5 years of age; 15 patients were 6 to 11 years of age.1
B-LONG was a phase 3 open-label study that investigated the safety and efficacy of ALPROLIX in 123 previously treated adult and adolescent patients aged ≥12 years with severe hemophilia B. The study included a fixed-interval (weekly) arm (n=63), a fixed-dose (interval-adjusted) arm (n=29), an episodic (on-demand) arm (n=27), and a surgical arm (n=12).1
PUPs B-LONG was a phase 3 open-label study that investigated the safety and efficacy of ALPROLIX in 33 PUPs aged <18 years with moderate or severe hemophilia B (≤2% endogenous factor IX activity). At enrollment, the median age was 0.6 years (range: 0.1-2 years).3
ABR=annualized bleed rate; PUP=previously untreated patient.
Pediatric and adult/adolescent dosing targets for on-demand treatment and control of bleeding episodes1
ALPROLIX prophylaxis offers bleed and joint bleed protection1†
†ALPROLIX has been proven to help patients prevent bleeding episodes using a prophylaxis regimen.1